Shaw AT, Ou SHI, Felip E, et al. Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. J Clin Oncol 35, 2017 (suppl; abstr 9006).
Trends in incidentie en overleving huidmelanoom
aug 2021 | Dermato-oncologie